Aquestive Therapeutics Inc. (AQST)
AQST trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/0001398733-26-000018-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AQST on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001398733 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $44.5M |
| Net income | -$83.8M |
| Operating income | -$71.1M |
| Net margin | -188.1% |
| Operating margin | -159.5% |
| Revenue growth | -22.6% |
| Cash | $121.2M |
| Total assets | $160.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 10.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $90.3M cash; operating cash flow -$9.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 125,687,705 (2026-10-30); 122,003,113 a year earlier; 66,767,283 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-06-26 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Short Hills, New Jersey, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $3.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $7.6M | -$16.5M | -$7.0M | $90.3M | $55.0M | $48.8M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $13.8M | -$22.9M | -$9.4M | $98.5M | $55.0M | $54.1M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $14.4M | -$8.1M | -$14.8M | $110.7M | $45.0M | $50.3M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $13.0M | -$31.9M | -$8.5M | $121.2M | $45.0M | $44.5M | 10-K 2026-03-04 |
| Q3 2025 2025-09-30 | $12.8M | -$15.4M | -$12.6M | $129.1M | $45.0M | $43.4M | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $10.0M | -$13.5M | -$7.9M | $60.5M | $45.0M | $44.1M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $8.7M | -$22.9M | -$23.4M | $68.7M | $45.0M | $54.2M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $11.9M | -$17.1M | -$6.5M | $71.5M | $45.0M | $57.6M | 10-K 2026-03-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-07-09 |
| Latest annual report | 10-K | 2026-03-04 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 692 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +8.3% |
| 1 month | -16.3% |
| 3 months | -8.0% |
| Year to date | -39.5% |
| 1 year | -26.2% |
| From 52-week high | -40.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| STTK | Shattuck Labs Inc. | $4.66 | +0.21% | $474.6M |
| OCS | Oculis Holding AG | $7.63 | -0.13% | $469.9M |
| LYEL | Lyell Immunopharma Inc. | $14.65 | +2.45% | $469.0M |
| KMDA | Kamada Ltd. | $8.11 | +0.25% | $468.0M |
| PHAT | Phathom Pharmaceuticals Inc. | $5.88 | -2.97% | $478.0M |
| NGNE | Neurogene Inc. Common Stock | $23.30 | -2.63% | $482.3M |
| CAPR | Capricor Therapeutics Inc. | $8.30 | -12.91% | $482.6M |
| MNPR | Monopar Therapeutics Inc. | $71.97 | -0.04% | $487.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier